An overview of the current genetic and phenotypical selection strategies to reduce the prevalence of feline hypertrophic cardiomyopathy = Een overzicht van de huidige genetische en fenotypische selectiestrategieën tegen hypertrofe cardiomyopathie bij de kat by Schipper, Tom et al.
Vlaams Diergeneeskundig Tijdschrift, 2020, 89 69
     BSTRACT
Hypertrophic cardiomyopathy (HCM) is a common and potentially lethal heart disease in 
cats. To reduce its prevalence, breeding cats are frequently screened on the basis of their phe-
notype or genotype. Although echocardiography is the most reliable phenotypical method, its 
efficacy is limited by the incomplete penetrance of HCM and by difficulties in distinguishing pri-
mary HCM from other causes of left ventricular hypertrophy. On the other hand, genetic testing 
is hampered by the genetic heterogeneity of the disease. Genetic tests are currently only available 
for Maine Coons and Ragdolls. Because of the high prevalence of HCM, stringent selection may 
have a negative impact on the genetic diversity of a breed. A more optimal selection would there-
fore be a slow and careful exclusion of phenotypically and/or genetically positive cats.
SAMENVATTING
Hypertrofe cardiomyopathie (HCM) is een veel voorkomende en potentieel dodelijke hartziekte bij 
katten. Fokkatten worden vaak gescreend voor deze ziekte, zowel op basis van hun fenotype als van 
hun genotype, om de prevalentie van deze aandoening te verminderen. Echocardiografie is de meest 
betrouwbare fenotypische techniek, maar de effectiviteit ervan wordt beperkt door de onvolledige 
penetrantie van HCM en het moeilijke onderscheid tussen primaire HCM en secundaire hypertrofie. 
Daar tegenover staat dat het gebruik van genetische testen wordt beperkt door de genetische 
heterogeniteit van de ziekte. Momenteel zijn genetische testen enkel beschikbaar voor de maine coon 
en de ragdoll. Vanwege de hoge prevalentie van HCM kan strenge selectie een negatief effect hebben 
op de genetische diversiteit van een ras. Geleidelijke en verstandige uitsluiting van positieve katten op 
basis van zowel fenotypische als genetische testen lijkt daarom een optimalere methode van selectie.
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INTRODUCTION
Hypertrophic cardiomyopathy (HCM) is the most 
common heart disease in cats, affecting almost 15% 
of the general population (Payne et al., 2015b). There 
is a strong suspicion that feline HCM, like human 
HCM, is inherited as a Mendelian disorder (Maron 
and Fox, 2015). The identification of causative vari-
ants in the Maine Coon and Ragdoll breeds has led 
to the development of genetic tests for these variants. 
Together with polycystic kidney disease, HCM is the 
feline disease, for which genetic testing is most of-
ten requested (Lyons, 2016). On the other hand, it has 
become common to screen breeding cats for HCM 
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phenotype by means of echocardiography (Häggström 
et al., 2015). Both methods have their advantages, but 
also serious limitations. Furthermore, considerable 
controversy exists around the genetic tests available 
for feline HCM, and breeders are not always aware 
that these tests are only appropriate in specific breeds 
(Lyons, 2012; Lyons et al., 2016). In this review, a 
general overview is provided of why genetic diseas-
es occur that often in companion animals. Secondly, 
the strategies for reducing the prevalence of HCM in 
purebred cats and the role of genetic testing and echo-
cardiography are discussed.
GENETIC  DISEASE  IN  COMPANION  ANIMALS
Unlike human populations, populations of do-
mestic animals generally have a low level of genetic 
diversity. They descent from relatively small popula-
tions that were domesticated and, more importantly, 
have been divided into small, genetically isolated sub-
populations by pedigree breeding (Jolly et al., 2016). 
Even in large breeds, few animals are used for breed-
ing, making these breeds somewhat similar to endan-
gered species (Traas et al., 2006). 
At the moment of their creation or at some point 
in their history, many breeds had a small number of 
reproducing animals (a population bottleneck) or a 
particularly popular sire with many descendants. Rare 
variants that were present in this small group or indi-
vidual animal have then been passed on to many ani-
mals within that breed. The spread of these initially 
rare variants in a population is called the founder ef-
fect (Jolly et al., 2016). When such a variant causes 
disease, that particular disease can become highly 
prevalent in that breed.
Breeding in a closed population with low genetic 
variability can not only cause the spread of genetic 
diseases in that breed, but also complicate elimination 
of such diseases. If the disease-causing variant is very 
common, abruptly excluding all animals that carry it 
from breeding, may have severe consequences. The 
genetic diversity of the breed may decrease further, 
variants encoding desirable traits may be lost and oth-
er disease-causing variants may increase in frequency 
(Traas et al., 2006). In the case of highly prevalent 
disease, it may therefore be wise to use some animals 
carrying a deleterious variant for breeding. In case 
of autosomal recessive disease, carriers and even 
affected animals can be safely bred with an animal 
that is confirmed to be homozygous wild type by a 
DNA-test (Mellersh, 2012). If the disease is inherited 
in an autosomal dominant fashion, breeding hetero-
zygotes to homozygous wild type animals generates 
offspring at risk for the disease. Nevertheless, such 
a way of breeding may be necessary to maintain ge-
netic diversity in a breed, in which that disease has a 
high prevalence. The carriers can then be replaced by 
animals from the next generation that are negative for 
this variant (Traas et al., 2006; Lyons, 2016).
CLINICAL  ASPECTS  OF  FELINE  HCM
Most of the cats affected by HCM are male do-
mestic shorthairs (Fox et al., 2018). It is not known 
what causes the high prevalence of HCM in domestic 
shorthairs, in which selective breeding is uncommon. 
If these cases are genetic, their causative variants may 
have become widespread because the late onset after 
breeding results in limited natural selection against 
them (Payne et al., 2015b). A breed predisposition has 
been suggested for several breeds, but these do not 
seem to be at an increased risk compared to domestic 
shorthairs (Côté et al., 2011a; Granström et al., 2011; 
Longeri. et al., 2013). A remarkably high prevalence 
or severe clinical course has however been reported 
in the Sphynx (Silverman et al., 2012), Ragdoll (Lef-
bom et al., 2001; Payne et al., 2010) and Maine Coon 
(Trehiou-Sechi et al., 2012), indicating that these 
breeds may indeed be predisposed for HCM.
HCM is characterized by concentric hypertrophy 
of the left ventricle that cannot be attributed to an-
other underlying disease. The hypertrophied ven-
tricle initially has a normal systolic function, but its 
increased stiffness, delayed relaxation and narrower 
lumen impair the filling during diastole. As a result of 
this diastolic dysfunction, pressure in the left atrium 
may rise, leading to atrial dilatation with a risk of left-
sided congestive heart failure or thrombus formation 
(Côté et al., 2011a). The electrophysiological conduc-
tion system of the heart can also be disturbed in HCM, 
making the heart prone to arrhythmias (Weissler-Snir 
et al., 2014; Bartoszuk et al., 2019).
Cats affected by HCM are born with a normal heart 
and only develop hypertrophy later in life (Kittleson 
et al., 1999). The age of onset and the progression of 
the hypertrophy differ widely between patients. Con-
siderable hypertrophy can develop without clinical 
signs, as long as the cardiac function is adequate. In 
many mildly affected cats, the disease remains in this 
occult stage, leaving them free of symptoms until they 
ultimately die from other causes (Trehiou-Sechi et al., 
2012). If the disease progresses to a clinical stage, 
asymptomatic cats may suddenly develop life-threat-
ening complications, such as cardiogenic pulmonary 
edema, pleural effusion or arterial thromboembolism. 
In some cases, sudden death, likely caused by ven-
tricular fibrillation, is the only clinical sign of the 
disease (Payne et al., 2015a). The incidence of lethal 
cardiovascular events in asymptomatic cats diagnosed 
with HCM is 6.3% per year (Fox et al., 2018).
No treatment is currently available to halt the pro-
gression of ventricular hypertrophy nor to prevent 
congestive heart failure or sudden cardiac death in 
cats, but prevention of arterial thromboembolism in 
high-risk cats is possible with clopidogrel (Hogan et 
al., 2015; Luis Fuentes and Wilkie, 2017). Treatment 
of arterial thromboembolism is often unsuccessful, 
while cats with congestive heart failure can have a 
good quality of life with combination therapy, usually 
a diuretic, platelet-inhibitor, ACE-inhibitor and some-
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times pimobendan (Reina-Doreste et al., 2014; Hogan 
and Brainard, 2015).
DETECTING HCM 
During the asymptomatic or “occult” stage of 
HCM, affected cats appear normal to the owner or 
breeder. Auscultation of these patients may reveal a 
heart murmur, gallop sound or arrhythmia. None of 
these findings is specific for HCM, and many affected 
cats show no abnormalities on auscultation (Payne 
et al., 2015b). Innocent heart murmurs are also very 
common in healthy cats and can be difficult to distin-
guish from pathological murmurs (Côté et al., 2015). 
Similarly, thoracic radiography and ECG may show 
nonspecific abnormalities, but are often unremark-
able in cats with occult HCM (Ferasin et al., 2003). 
Cardiac biomarkers, such as N-terminal pro-brain na-
triuretic peptide (NT-proBNP) and cardiac troponin 
I (cTnI), are an attractive screening tool because of 
their low cost and easy use. However, there is some 
overlap in the concentrations of such biomarkers be-
tween healthy cats and cats with asymptomatic HCM 
(Fox et al., 2011; Hertzsch et al., 2019). Further-
more, increased levels of cardiac biomarkers can also 
be caused by other diseases, as has been shown for 
chronic kidney disease (Porciello et al., 2008), hyper-
thyroidism (Sangster et al., 2014) and hypertension 
(Bijsmans et al., 2017) in cats.
Echocardiography is considered the gold standard 
for diagnosing HCM in cats. The main criterion is the 
thickness of the left ventricular free wall and interven-
tricular septum. In general, an end-diastolic thickness 
< 5.5 mm at the level of the papillary muscles is con-
sidered normal, a thickness > 6.0 mm is diagnostic for 
HCM and measurements in between can be classified 
as equivocal (Côté et al., 2011a). If wall measurements 
are within the reference ranges, abnormalities of the 
papillary muscles or mitral valve might still lead to a 
classification as equivocal (Häggström et al., 2015). 
A general cut-off for wall thickness does not take into 
account that the normal values may differ between 
breeds, as they are for example lower in Sphynxes 
(Chetboul et al., 2012) than in Bengals (Scansen et 
al., 2015), nor does it take into account that these 
values increase with body weight (Häggström et al., 
2016). Another difficulty is that in affected cats, the 
hypertrophy is not always generalized, but may also 
be confined to certain left ventricular segments or 
the papillary muscles (Fox, 2003). Finally, multiple 
methods of imaging and measuring are applied in 
practice. Altogether, these factors allow for consider-
able variation in classification, especially in equivocal 
cases. In one study on apparently healthy shelter cats, 
the prevalence of left ventricular hypertrophy ranged 
from 12% to 51% depending on the chosen cut-off 
(6.0 mm or 5.5 mm, respectively) and scanning mode 
(M-mode or 2D B-mode, respectively) (Wagner et al., 
2010).
Similar to feline HCM, the diagnosis of the human 
HCM phenotype is based on the end-diastolic thick-
ness of the myocardial wall, which may be assessed 
by echocardiography, CT or MRI. The cut-off recom-
mended by the European Society of Cardiology is 15 
mm in adults, 13 mm in first-degree relatives of diag-
nosed patients and two standard deviations above the 
population mean in children (Elliott et al., 2014).
Underlying diseases may cause left ventricular 
hypertrophy due to hormonal influences as in hyper- 
thyroidism, acromegaly and hyperaldosteronism, 
or due to abnormal loading conditions as in hyper- 
tension and aortic stenosis (Stowasser et al., 2005; 
Côté et al., 2011a). HCM can also be mimicked by 
wall thickening due to edema or infiltrative diseases, 
such as myocarditis or myocardial lymphoma. Final-
ly, hypovolemic cats may display pseudohypertrophy 
due to the reduced size of the left ventricular chamber 
(Côté et al., 2011a). A certain diagnosis of HCM re-
quires the exclusion of these diseases, which may be 
relatively simple (e.g. measurement of blood pressure 
or total thyroxine level), but can also be complicated 
(e.g. in case of infiltrative disease). However, these 
differential diagnoses are either rare or less likely in 
cats of breeding age (Häggström et al., 2015). In some 
cases, mainly young cats with congestive heart fail-
ure after an antecedent stressful event, concentric left 
ventricular hypertrophy may spontaneously regress, 
a condition named transient myocardial thickening 
(TMT) (Novo Matos et al., 2018). At first presenta-
tion, it is not possible to distinguish TMT from early-
onset HCM (Novo Matos et al., 2018).
In conclusion, despite being considered the gold 
standard, echocardiographic diagnosis of HCM in 
cats is not straightforward. It is a diagnosis of ‘exclu-
sion’ that requires thorough knowledge of other dis-
eases causing left ventricular hypertrophy and expert 
echocardiography skills. Furthermore, there is a sig-
nificant overlap in the echocardiographic phenotype 
between HCM and several other feline cardiomyopa-
thies (ACVIM consensus statement on feline cardio-
myopathy, in press).
GENETIC ASPECTS OF HUMAN AND FELINE 
HCM
Feline HCM shows remarkable similarities in 
morphology and clinical course to human HCM, and 
it is likely that these diseases also share genetic as-
pects (Maron and Fox, 2015; Freeman et al., 2017). 
HCM is the most common inherited heart disease in 
humans and 60% of the patients indeed have a clear 
family history of HCM. In nearly all familial cases, 
the disease is inherited in an autosomal dominant pat-
tern. However, HCM generally does not show full 
penetrance. The penetrance is the probability that an 
individual with a disease-causing genotype displays 
the disease (Broeckx et al., 2017). Because the HCM 
phenotype is usually not detectable at birth and only 
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develops later in life, the penetrance is said to be age-
dependent. The penetrance is also incomplete, as some 
people carrying a causative variant never develop the 
HCM phenotype (Marian and Braunwald, 2017). The 
penetrance seems to be higher in men than in women, 
but the male overrepresentation is less pronounced 
than in cats (Olivotto et al., 2005).
The molecular genetic basis of human HCM was 
first identified in a family with a variant in MYH7, 
the gene that encodes the ventricular myosin heavy 
chain protein. This was soon followed by many other 
variants in the same gene as well as in other genes 
(Marian and Braunwald, 2017). Today, more than 
1.500 variants in over fifty genes have been linked to 
HCM, but for many variants and genes, the causality 
has been disputed (Walsh et al., 2017; Ingles et al., 
2019). Nevertheless, a large number of variants have 
been proven to cause HCM. This situation, in which a 
disease is caused by many different variants, is called 
genetic heterogeneity. A few HCM-causing variants 
are common in a specific population, suggesting a 
founder effect, but most are restricted to a few fami-
lies or a single family (Marian and Braunwald, 2017). 
Definitive evidence for a role in HCM has been 
provided for eight sarcomeric genes (ACTC1, MYBPC3, 
MYH7, MYL2, MYL3, TNNI3 and TNNT2) (Walsh et 
al., 2017; Ingles et al., 2019). In 50% of the patients 
in whom a causative variant is identified, this variant 
lies in MYBPC3, that codes for the myosin-binding 
protein C, or MYH7, making these two genes the most 
important in human HCM (Marian and Braunwald, 
2017).
The identification of a causative variant in a pa-
tient allows the screening of family members for this 
variant. This has led to the identification of genotype-
positive - phenotype-negative patients, who carry a 
causative variant without displaying ventricular hy-
pertrophy, but who are nevertheless considered at risk 
of sudden death (Maron et al., 2011). On the other 
hand, no causative variant is found in a large number 
of patients who display the HCM phenotype (Marian 
and Braunwald, 2017). This shows that the phenotype 
and genotype of HCM, and therefore the diagnostic 
test based on either of them, do not fully overlap. As 
in cats, human HCM shows extensive variation in the 
progression and outcome of the disease. There is no 
clear relationship between the causative variant and 
the clinical manifestation of the disease: the same 
variant may lead to sudden cardiac death at young 
age in one patient, but cause no clinical signs at all 
in another patient (Landstrom and Ackerman, 2010). 
Although the cause of the disease is a deleterious 
sarcomeric variant, variants in other genes, such as 
genes of the renin-angiotensin-aldosterone system, as 
well as epigenetic and environmental factors seem to 
strongly modify the phenotype of a patient (Sabater-
Molina et al., 2018).
HCM has also been described as a familial dis-
ease in cats, although the documentation is far more 
limited in cats than in humans. Familial occurrences 
of HCM have been reported in American Shorthairs 
(Meurs et al., 1997), British Shorthairs (Putcuyps 
et al., 2003), Maine Coons (Kittleson et al., 1999), 
Norwegian Forest Cats (März et al., 2015), Persians 
(Martin et al., 1994) and Sphynxes (Chetboul et al., 
2012; Silverman et al., 2012), as well as Domestic 
Shorthairs (Baty et al., 2001; Krauss et al., 1999; Na-
kagawa et al., 2002). Although pedigree data is often 
limited, these reports are compatible with an autoso-
mal pattern of inheritance. In some cases, it has been 
suggested that the penetrance is incomplete (Chetboul 
et al., 2012; März et al., 2015).
HCM-CAUSING  VARIANTS  IN  CATS
The first HCM-causing variant identified in cats 
was MYBPC3 c.91G>C, a change from guanine to 
cytosine at the 91th coding position of the MYBPC3 
gene (Meurs et al., 2005; reference sequence: 
XM_019812396.1). This variant was first found in a 
research colony of Maine Coons where HCM seemed 
to segregate according to an autosomal dominant pat-
tern (Kittleson et al., 1999). The variant then turned 
out to be present in over 30% Maine Coons around the 
world (Fries et al., 2008), but to be extremely rare in 
other breeds (Mary et al., 2010; Longeri et al., 2013).
In the colony where the variant was first found, 
HCM developed in all homo- and heterozygotes, 
though more severe in the homozygotes (Meurs et 
al., 2005). However, in subsequent studies in client-
owned Maine Coons, it has been found that many 
cats carrying the variant are phenotypically normal, 
leading to doubts about the clinical significance of 
this variant or about its proposed mode of inheritance 
(Wess et al., 2010; Longeri et al., 2013). 
To provide more evidence for the mode of inheri-
tance and optimal breeding advice, a meta-analysis of 
five studies has been performed (Mary et al., 2010; 
Wess et al., 2010; Godiksen et al., 2011; Longeri et 
al., 2013; Pellegrino et al., 2017). In this meta-anal-
ysis, the penetrance of HCM was found to be 0.04 in 
homozygous wild type Maine Coon cats. The pene-
trance in heterozygous cats is very similar (0.07; P 
= .23), while it is much higher (0.54; P < .001) in 
homozygous variant cats. These studies therefore do 
not confidently show a clinical effect of the variant in 
heterozygotes and suggest that if there is such an ef-
fect, it is likely to be small. An important limitation of 
these studies is that most investigated cats were young 
females, which may not yet have developed the HCM 
phenotype. Although the actual penetrance would 
probably have been higher overall if these cats had 
been older, the ages of the different genotype groups 
in the studies were comparable. As such, it is unlike-
ly that young age can explain why the penetrance in 
heterozygotes is lower than the penetrance in homo-
zygous variant cats and similar to the penetrance in 
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homozygous wild type cats. The presence of HCM in 
wild type cats implies that HCM in Maine coons can 
also arise due to other causes, either genetic or envi-
ronmental (Longeri et al., 2013).
A second variant in the same gene in Maine Coons, 
MYBPC3 c.220G>A, has also been proposed to be as-
sociated with HCM in an abstract by Nyberg et al. 
(2007). This variant is not specific for Maine Coons, 
as it has been found in many other breeds as well as 
in Domestic Shorthairs (Longeri et al., 2013). How-
ever, in subsequent studies, no convincing evidence 
has been found that this variant causes HCM in cats 
(Wess et al., 2010; Longeri et al., 2013).
An HCM-causing variant in Ragdolls, the MYBPC3 
c.2455C>T variant, has been identified by sequenc-
ing the MYBPC3 gene in client-owned affected cats 
(Meurs et al., 2007). Again, the variant was found in 
approximately 30% of the Ragdolls, but not in other 
breeds (Longeri et al., 2013; Casamian-Sorrosal et 
al., 2014). Fewer studies are available on this vari-
ant than on the MYBPC3 c.91C>G variant, but cats 
carrying this variant have an increased wall thickness 
than wild type cats (Borgeat et al., 2015). In a small 
study population, the overall penetrance for homo- 
and heterozygotes was 0.33 (Borgeat et al., 2015). In 
a survey  filled out by Ragdoll owners, a high risk of 
cardiac death was found in cats homozygous for the 
variant, while the risk in heterozygotes was not dif-
ferent from the risk in wild type cats (Borgeat et al., 
2014). The same variant has also been identified as a 
cause of cardiomyopathy in humans (Ripoll Vera et 
al., 2010). Some Ragdolls diagnosed with HCM are 
negative for the MYBPC3 c.2455C>T variant, again 
indicating that there are also other causes of HCM in 
this breed (Borgeat et al., 2015).
A variant in MYH7, c.5647G>A, has recently 
been identified as the cause of HCM in a Domestic 
Shorthair (Schipper et al., 2019; reference sequence: 
XM_006932746.4). The same variant has been iden-
tified in a HCM-affected human patient (Taisjharghi 
et al., 2007) and a homologous variant in MYH6 is 
known to cause cardiac disease in humans (Bowles 
et al., 2015; Preuss et al., 2016). The variant affects 
an important functional domain of the protein and has 
been shown to have a damaging effect in functional 
studies (Sohn et al., 1997; Viswanathan et al., 2017). 
In the study that identified this variant, the variant was 
absent in two hundred other cats, of which most were 
considered HCM-negative. Although very little fam-
ily information was available, the cat affected by the 
variant was a heterozygote and an autosomal domi-
nant pattern of inheritance seemed most likely (Schip-
per et al., 2019).
The high prevalence of the MYBPC3 c.91G>C 
and c.2455C>T variants within the Maine Coon and 
Ragdoll breeds, together with their absence in other 
breeds, suggests that these variants have been spread 
by the founder effect. However, the finding of variant-
negative cats with HCM makes it likely that there are 
more causative variants in these breeds and that feline 
HCM, like human HCM, knows considerable genetic 
heterogeneity.
SCREENING  BREEDING  ANIMALS  FOR 
DISEASE-CAUSING  VARIANTS
The high prevalence of genetic diseases in pure-
bred animals has led to the development of screening 
programs for breeding animals. These programs pri-
marily aim to reduce the prevalence of genetic disease 
by preventing matings that may produce offspring at 
risk (Meyers-Wallen, 2003). Concerns about animal 
welfare, self-interest of breeders and owners and pub-
lic pressure to increase the health of purebred animals 
may all be motivations to participate in screening pro-
grams (Mellersh, 2012; Jolly et al., 2016). Prioritiza-
tion of genetic diseases for screening can be based on 
the prevalence and severity of the diseases (Collins et 
al., 2011). Screening programs depend on diagnostic 
tests that identify animals that can transmit the dis-
ease. Ideally, a diagnostic test is cheap, minimally 
invasive and requires minimal time and expertise to 
perform (Drobatz, 2009). The test can either be a phe-
notypical or a genetic test.
Phenotypical tests select breeding animals on the 
basis of clinical features. They have the advantage 
that no knowledge of the underlying genetic cause is 
required. However, they cannot detect heterozygous 
carriers of recessive alleles or animals that are geneti-
cally at risk but do not display the disease due to in-
complete penetrance. Another possible problem is a 
late age of onset, in which case affected animals may 
already have offspring at the time of diagnosis (Mel-
lersh, 2012). 
Genetic tests require DNA, often isolated from 
EDTA blood. By methods such as PCR, Sanger se-
quencing or restriction enzyme fragment length poly-
morphism, the disease-causing variant can be directly 
detected (Jolly et al., 2016). This circumvents the 
problem of incomplete penetrance; however, these 
tests are only possible when the disease-causing vari-
ant is known. Furthermore, there should be convinc-
ing evidence that this variant indeed causes the dis-
ease. Selection against a common variant that has no 
clinical significance can needlessly reduce the genetic 
variability of a breed (Lyons et al., 2016).
Genetic screening against a widespread causative 
variant, as in cases of a founder effect, can be very 
effective in reducing the prevalence of a disease. In 
cases of genetic heterogeneity, selection against a few 
uncommon causative variants amongst many variants 
has a far lower impact (Meyers-Wallen, 2003). 
The high prevalence, risk of agonizing or lethal 
complications and limited treatment options are rea-
sons to give HCM high priority among feline genetic 
diseases. The age-dependent and incomplete pene-
trance can preclude (early) phenotypical detection of 
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breeding animals that carry a causative variant. Echo-
cardiography, the preferred phenotypical test, requires 
a high level of expertise and even experts can have 
difficulties in distinguishing mildly affected animals 
from normal animals (Häggström et al., 2015). On the 
other hand, the genetic background of feline HCM 
seems to be a combination of both highly prevalent, 
breed-specific variants and rare variants that display 
significant heterogeneity. This heterogeneity will 
make genetic screening only partially effective.
Phenotypical selection could be complemented by 
pedigree analyses. The HCM status of close relatives 
can help to identify cats at high risk of carrying HCM-
causing variants, whose use in breeding should be 
postponed until they are shown to be free of the HCM 
phenotype at mature age (Häggström et al., 2015). The 
use of pedigrees to obtain estimated breeding values, 
as advocated for hip dysplasia selection, seems less 
applicable, as HCM is considered a qualitative rather 
than a quantitative trait (Wilson et al., 2011).
The high prevalence and potentially severe con-
sequences of HCM may also be seen as reasons for 
population-wide screening of all cats. However, such 
extensive efforts are only justified if a number of con-
ditions are met, including the availability of cheap di-
agnostic tests and effective treatment (Shaw, 2017). 
The low availability of expert echocardiographers and 
the limited treatment options for feline HCM do not 
fulfill these criteria.
RECOMMENDATIONS FOR SCREENING IN 
BREEDS FOR WHICH NO GENETIC TEST IS 
AVAILABLE
There are no suitable genetic tests for other breeds 
than the Maine Coon and Ragdoll (Côté et al., 2011b). 
For these other breeds, phenotypical screening is the 
only available method of screening for HCM. This 
should be based on echocardiography performed by 
an experienced echocardiographer. Other methods 
(e.g. thoracic radiography alone) carry a high risk of 
false negatives, allowing the transmission of deleteri-
ous variants, or false positives, unnecessarily exclud-
ing healthy animals from breeding. Measurements 
of cardiac biomarkers with validated assays can be 
used to identify cats at an increased risk. However, 
this should always be followed by an echocardiog-
raphy (in combination with ancillary diagnostic test-
ing if necessary) to confirm or exclude the diagnosis 
of primary HCM. Recommended screening schemes 
consist of an annual examination by an experienced 
cardiologist during the period that the cat is used for 
breeding and a follow-up examination at the age of 
five to eight years (Häggström et al., 2015).
Phenotypical screening for HCM is currently per-
formed in the Siberian, Norwegian Forest Cat, British 
Shorthair/Longhair, Bengal, Birman, Cornish and Da-
von Rex, Sphynx and Persian/Exotic in the PawPeds 
program (www.pawpeds.com), which is the largest 
Figure 1. Recommendations for screening and breeding to reduce the prevalence of HCM in cats. Vt/Vt = homozygous 
for the disease-causing variant, Wt/Vt = heterozygous, Wt/Wt = homozygous wild type.
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international HCM screening program (Häggström et 
al., 2015). However, HCM also occurs in other breeds, 
of which some, such as the Chartreux and American 
Shorthair, have been described as predisposed (Côté 
et al., 2011b; Maron and Fox, 2015; Fox et al., 2018). 
Other breeds may therefore be added to this list. 
RECOMMENDATIONS FOR SCREENING IN 
BREEDS FOR WHICH GENETIC TESTS ARE 
AVAILABLE
Genetic testing is possible for all four variants re-
ported as causative for HCM, but this is not necessar-
ily recommended. As there is no convincing evidence 
that the MYBPC3 c.220G>A variant causes disease, 
there is a general consensus that screening for this 
variant is not recommended for any breed (Wess et 
al., 2010; Côté et al., 2011b; Longeri et al., 2013; 
Häggström et al., 2015; Lyons, 2015).
The incomplete penetrance of the MYBPC3 
c.91G>C variant has made some authors to advise 
against screening for this variant (Wess et al., 2010). 
However, as this variant increases the risk of HCM 
(especially in homozygotes), many authors recom-
mend the genetic test in Maine Coons (Côté et al., 
2011b; Longeri et al., 2013; Lyons , 2015). Less in-
formation is available on the MYBPC3 c.2455C>T 
variant, but Borgeat et al. (2014) advise to take this 
variant into account in Ragdolls because of the in-
creased risk of early cardiac death in homozygotes. 
The two variants have a high prevalence within the 
Maine Coon and Ragdoll breed, respectively, but 
they are virtually absent in other breeds (Longeri et 
al., 2013; Cassamian-Sorrosal et al., 2014). The au-
thors therefore recommend to screen for the MYBPC3 
c.91G>C and c.2455C>T variants in Maine Coons 
and Ragdolls, respectively, but not in other breeds. As 
the MYH7 c.5647G>A variant has only been found in 
a single Domestic Shorthair, the authors expect it to 
be very rare and do not recommend testing for this 
variant in any breed. The authors’ recommendations 
for the use of genetic variants for screening against 
HCM are summarized in Table 1.
Because of the occurrence of HCM in Maine Coons 
and Ragdolls negative for these variants, it is possible 
that other genetic factors in these breeds also contri-
bute to HCM. After selecting potential breeding cats 
with genetic tests, it is therefore recommended to also 
evaluate these cats by echocardiography in the same 
way as cats of other breeds (Häggström et al., 2015). 
The genetic tests allow selection against variants with 
low penetrance, which are unlikely to be detected by 
echocardiography, while the echocardiography may 
identify animals carrying disease-causing variants, 
for which no genetic test is available.
RECOMMENDATIONS  FOR  BREEDING
Assuming the proposed autosomal dominant pat-
tern of inheritance, it is in theory not recommended to 
use Maine Coons or Ragdolls that are either hetero-
zygous or homozygous for the MYBPC3 c.91G>C or 
c.2455C>T variant for breeding. However, given the 
high prevalence of these variants and the apparently 
low penetrance in heterozygotes, it might be neces-
sary to make exceptions to this rule (Mellersh, 2012). 
A rapid elimination of all cats carrying these variants 
from breeding may have undesirable consequences 
and therefore, a slow eradication is advised (Lyons, 
2016). Given the strongly increased risk of HCM and 
cardiac death in homozygotes, the authors consider 
the prevention of mating that may produce homozy-
gotes while maintaining genetic variation, as the main 
goal of selection on the basis of genotype.
Côté et al. (2011b) advise to retain positive cats 
with desirable characteristics as breeding animals, 
but under three conditions: Firstly, they should be 
heterozygotes, as they pass on the variant to 50% of 
their offspring (compared to 100% for homozygous 
cats). Secondly, cats selected for breeding should only 
be mated to cats that are negative for this variant, to 
avoid homozygous kittens, which have the highest 
risk to develop HCM. Thirdly, they should be nega-
tive for the HCM phenotype on echocardiography. 
Testing kittens of these litters allows selection of 
negative animals for future breeding (Lyons, 2016). 
In this way, the prevalence of a disease-causing vari-
ant may be decreased slowly in a population without 
deleterious side effects (Côté et al., 2011b).
When screening on the basis of the phenotype, af-
fected cats should be excluded from breeding. In prin-
ciple, no distinction should be made between mild 
and severe cases in the context of breeding: the causa-
tive variant may be identical in these cases and the 
difference could be solely due to other genetic and/
or environmental factors. As these modifying factors 
Table 1. Currently known HCM-causing variants in cats, the breed(s) in which they occur and their application in 
screening. 
Variant Breed Recommended to use for screening?
MYBPC3 c.91C>G Maine Coon Yes, but only in Maine Coons
MYBPC3 c.220G>A Multiple breeds No, because the pathogenicity is not proven
MYBPC3 c.2455C>T Ragdoll Yes, but only in Ragdolls
MYH7 c.5647G>A Domestic Shorthair No, because the prevalence is low
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might be different in the offspring, mildly affected 
cats may have severely affected offspring and vice 
versa (Lyons, 2016). When findings are equivocal, 
breeding can be postponed until more certainty about 
the diagnosis is obtained by a re-examination after six 
to twelve months (Häggström et al., 2015). An over-
view of recommendations for screening and breeding 
is provided in Figure 1.
The proportion of cats that are diagnosed with the 
HCM phenotype at breeding age is estimated rela-
tively low at 3-5%, suggesting that eliminating all 
positive cats has a limited effect on genetic diver-
sity (Häggström et al., 2015). Nevertheless, in some 
breeds where the prevalence of HCM seems high, 
such as the Sphynx, stringent selection might have 
negative consequences (Chetboul et al., 2012). In 
such cases, it is advisable to also consider mating af-
fected animals to healthy animals. Cats that have mild 
and late-onset HCM could be selected, although this 
does not guarantee that these cats are not homozygous 
for a HCM-causing variant.
FUTURE PERSPECTIVES
The application of genetic tests for screening 
breeding cats against HCM is currently limited as 
only a few variants are known to cause this apparently 
heterogeneous disease. The utility of genetic testing 
could be much improved by the identification of new 
HCM-causing variants. The increased use of next-
generation sequencing and genome-wide association 
techniques in cats may facilitate the search for such 
variants (Gandolfi et al., 2018; Ontiveros et al., 2018).
If the genetic background of HCM is as hetero-
geneous in cats as it is in humans, trying to identify 
and select against all causative variants is a futile 
effort. Nevertheless, identifying the most common 
causative variants in breeds where HCM is a major 
problem may provide a tool for careful elimination of 
these variants. This might already strongly reduce the 
prevalence of HCM in a breed. Furthermore, because 
homozygosity is most likely for a variant with a high 
frequency, the elimination of common variants will 
reduce the number of homozygotes, which generally 
have a worse prognosis than heterozygotes. In a study 
on eight DNA tests for canine recessive diseases, each 
test led to a decline in the number of affected dogs as 
well as a decline in the frequency of the causative al-
lele, illustrating the effectiveness of genotypical selec-
tion (Lewis and Mellersh, 2019). Casamian-Sorrosal 
et al. (2014) found significantly fewer Maine Coons 
homozygous for the MYBPC3 c.91G>C variant than 
expected under Hardy-Weinberg equilibrium, but it 
is not known whether this was the result of selective 
breeding.
As long as most genetic causes are unknown, 
echocardiography remains the principal screening 
method. The effectiveness of the current echocardio-
graphic screening programs in reducing the preva-
lence of feline HCM is not known (Häggström et al., 
2015). For dogs however, the effectiveness of cardiac 
screening programs has been analyzed. In a study by 
Birkegård et al. (2016), Cavalier King Charles Span-
iels registered in the Danish kennel club, which re-
quires that the parents are free from a relevant heart 
murmur on auscultation and mitral valve prolapse on 
echocardiography, had a lower risk of signs of de-
generative mitral valve disease than dogs that were 
not registered. In a study of a compulsory Swedish 
scheme using auscultation alone, no effect was found, 
but this may be caused by the small number of dogs 
and the short duration of the study (Lundin and Kvart, 
2010). In a large, long-term study in the UK, a very 
limited effect was found, probably because it relied 
on auscultation alone and/or because screening was 
not mandatory for registration and the compliance by 
the breeders was low (Swift et al., 2017). Although 
degenerative mitral valve disease is considered poly-
genic while HCM is monogenic, these results suggest 
that phenotypical selection against acquired heart dis-
ease can be effective, but only if the diagnostic test is 
adequate and the breeder compliance is high.
Because the efficacy of echocardiography is limi-
ted by the penetrance and that of genetic testing is 
limited by genetic heterogeneity, one method cannot 
fully replace the other. In an ideal situation, the tests 
are used complementary and breeders can combine 
the results to select the cats that are least likely to get 
offspring at risk of HCM.
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